Answers are grounded in this paper and cite their sources.
Objective: This review paper provides an extensive comparative analysis of how the United States Food and Drug Administration (US FDA), European Medicines Agency (EMA), and India's Central Drugs Standard Control Organisation (CDSCO) govern AI-driven Software as a Medical Device (SaMD) algorithms. It focuses specifically on the operational deployment of Generative AI (GenAI) in automated regulatory document compilation, tracking the shift from standard electronic submissions to automated lifecycles.
No takes yet. Share an insight, caveat, or question.
Jagtap et al. (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: